Liberty, equality, fraternity. Liberté, égalité, fraternité.

Also in the December issue: 5-year outcomes after stereotactic ablative body #radiotherapy for primary #renalcellcarcinoma #kidneycancer: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) thelancet.com/journals/lanon…

Great results from the OPERA trial: dose escalation with contact x-ray brachytherapy boost improves organ preservation at 3-yrs in early rectal adenoCA compared to CRT with boost up to 54Gy (97% vs 63% for tumors <3cm and 81% vs 59% for all tumors <5cm) thelancet.com/journals/langa…

redjournal.org/article/S0360-…

36.25 Gy/5 fx linac-based prostate SBRT with 32.5 Gy urethra-sparing delivered every-other-day or once-a-week. Minimal impact on tox and QoL regardless of OTT: 5-yr G2+ GU and GI tox-free survival ~76% and ~90%; 5-yr bRFS >90% redjournal.org/article/S0360-…

Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001 redjournal.org/article/S0360-…

Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: nej.md/3N8N5dU

PEACE-1: Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive #ProstateCancer (mCSPC): ☢️ Radiotherapy (RXT) of the prostate 74 Gy in 37 fractions (after docetaxel is completed) improve rPFS (median of 7.5 year) mOS not significant! ☢️minimal

Prostate #radiation continues to show incredible benefits in #mHSPC. #RT shows synergistic effect with #abiraterone. Significant improvement in #rPFS with delay in time to serious #GU events. Dr. Alberto Bossi, #PEACE1 #ASCO2023 #PCSM

thegreenjournal.com/article/S0167-…

Can you spot the Snow Leopard?

🎙️why should HIFU not be offered for prostate cancer patients ⁉️ Eur Urol Focus 📌Cohort study 50 👥w/ ISUP GG ≤2 & PSA <10 ng/ml ➡️ mpMRI/TRUS fusion-guided HIFU for localized prostate cancer 📊results 🥇🎯: 1-yr cancer-free rate of HIFU-treated lesion 👉Median PSA ⤵️ from

Brachytherapy gets the job done! Congrats on this important work!

🧠🧪Lapatinib & brain RT (WBRT or SRS) in Her2+ breast cancer: 📖randomized phase II 🔸association not improved 12-week CR or ORR ➡️suggest short-term benefit from concomitant therapy : ORR 55% vs 42% at 4 weeks p=0,14 OncoAlert #OncoAlertAF IJROBP - The Red Journal redjournal.org/article/S0360-…

These French GFRU prostate RT guidelines always seem to be very popular! Many thoughtful refinements (but still arguing with NRG Oncology) 😂😂😂 At: redjournal.org/article/S0360-…

Delighted to publish the very long term results of our phase II SBRT boost in intermediate risk prostate cancer. Very low rate of G2+ late GU toxicity A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boos... sciencedirect.com/science/articl…

🎙️ docetaxel should not be used for high-risk localized #prostatecancer❗️OncoAlert European Urology 📌Ph III RTOG 0521 trial w/ 612 👥; HR localized #prostatecancer randomize to ADT + EBRT✖️ADT + EBRT + docetaxel 🥇🎯:OS 📊RESULTs 👉10-y OS : 64% ADT + EBRT✖️69% ADT + EBRT +

thegreenjournal.com/article/S0167-…

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology – work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

Just out in ⁦JAMA Oncology⁩ on safety and efficacy of relugolix with RT from IPD from 2 RCTs: Take home points: - faster T suppression by ~3 wks vs lupron - deeper T suppression - faster T recovery - no difference in time to CRPC ⁦RadOncUH⁩ jamanetwork.com/journals/jamao…